Gestiva Passes Cmte. Review, But Further Study Of Miscarriage Risk Requested
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Reproductive Health Advisory Committee votes that safety and efficacy of Adeza’s preterm birth agent Gestiva have been demonstrated.